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Abstract
Background: Meropenem is a carbapenem that has an excellent activity against many gram-positive and gram-
negative aerobic, facultative, and anaerobic bacteria. The major objective of the present study was to assess the in vitro 
activity of meropenem compared to imipenem and piperacillin/tazobactam, against 1071 non-repetitive isolates 
collected from patients with bacteremia (55%), pneumonia (29%), peritonitis (12%) and wound infections (3%), in 15 
French hospitals in 2006. The secondary aim of the study was to compare the results of routinely testings and those 
obtained by a referent laboratory.
Method: Susceptibility testing and Minimum Inhibitory Concentrations (MICs) of meropenem, imipenem and 
piperacillin/tazobactam were determined locally by Etest method. Susceptibility to meropenem was confirmed at a 
central laboratory by disc diffusion method and MICs determined by agar dilution method for meropenem, imipenem 
and piperacillin/tazobactam.
Results: Cumulative susceptibility rates against Escherichia coli were, meropenem and imipenem: 100% and 
piperacillin/tazobactam: 90%. Against other Enterobacteriaceae, the rates were meropenem: 99%, imipenem: 98% and 
piperacillin/tazobactam: 90%. All Staphylococci, Streptococci and anaerobes were susceptible to the three antibiotics. 
Against non fermeters, meropenem was active on 84-94% of the strains, imipenem on 84-98% of the strains and 
piperacillin/tazobactam on 90-100% of the strains.
Conclusions: Compared to imipenem, meropenem displays lower MICs against Enterobacteriaceae, Escherichia coli and 
Pseudomonas aeruginosa. Except for non fermenters, MICs90 of carbapenems were <4 mg/L. Piperacillin/tazobactam 
was less active against Enterobacteriaceae and Acinetobacter but not P. aeruginosa. Some discrepancies were noted 
between MICs determined by Etest accross centres and MICs determined by agar dilution method at the central 
laboratory. Discrepancies were more common for imipenem testing and more frequently related to a few centres. 
Overall MICs determined by Etest were in general higher (0.5 log to 1 log fold) than MICs by agar dilution.
Background
Antimicrobial susceptibility surveillance programmes
represent one of the main recommendations to control
resistant organisms, providing essential information in
order to improve the quality of empiric antimicrobial pre-
scribing or guiding development of antimicrobial poli-
cies. National and regional distributions of the data are
important to enable local prescribing practices. The car-
bapenem (meropenem, imipenem)? with activity against
P. aeruginosa have been the most active broad-spectrum
antimicrobial class documented by numerous large sur-
veillance programs [1]. One of the most cited global sur-
veillance studies includes the Meropenem Yearly
Susceptibility Test Information Collection (MYSTIC)
program, an international resistance surveillance study
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Page 2 of 9which has been initiated 10 years ago with more than 100
participants worldwide [2-9]. The MYSTIC program is
considered as a valuable tool to recognize the emergence
of carbapenem and broad spectrum resistance mecha-
nisms. An observatory surveillance system was estab-
lished in 2006 to monitor the in vitro activity of
meropenem following its approval in France in 2006 [10].
The major objective of the present study was to assess the
in vitro activity of meropenem which has been recently
re-introduced in French hospitals, compared to imi-
penem and piperacillin/tazobactam, against clinical iso-
lates included in the spectrum of meropenem. One
thousand and seventy one pathogens responsible for
severe nosocomial infections were collected from 15 geo-
graphically diverse institutions in France. The secondary
aim of the study was to compare the results of routinely
testings and those obtained by a central laboratory.
The 15 French microbiology laboratories conducted
susceptibility testing by disk diffusion test or broth dilu-
tion method according to the CA-SFM (Comité de l'Anti-
biogramme de la Société Française de Microbiologie)
recommendations [11]. Since the participants of the 15
laboratories were using the CA-SFM breakpoints and
because the EUCAST breakpoints will be introduced
soon in France, approved CA-SFM and EUCAST (Euro-
pean Committee for Antimicrobial Susceptibility Testing
[12]) interpretative breakpoints were used. The results
obtained by the different laboratories (MICs by Etest
method) were compared to those obtained by the central-
ized agar dilution method.
Methods
Fifteen French Community and Universitary Hospital
Centres participated in this study and were chosen to
represent geographically separate areas. Clinical isolates
were collected between January and June 2006.
Isolates
The study protocol outlined specific quotas per medical
centre among E. coli and other Enterobacteriaceae, non
fermenter Gram-negative bacilli, Staphylococci, Strepto-
coccus pneumoniae and anaerobes, for a total of 80 bacte-
rial strains. Each centre collected the first 20 clinically
relevant non-repetitive isolates of each selected species
from patients hospitalized in 2006 with nosocomial infec-
tions: bacteremia, peritonitis, pulmonary infections and
wound infections. Clinical and microbiological relevance
was defined by "100 recommendations on nosocomial
infections" from the French Health Ministry [13]. Species
or genera known to be resistant to meropenem (methicil-
lin-resistant -Staphylococci, Enterococccus faecium and
Stenotrophomonas maltophilia) were excluded from the
study collection.
Antimicrobial susceptibility methods
Antibiotic susceptibility testing was carried out using the
local centre routine methods (Vitek, Etest, disk diffusion
method). Susceptibilities were determined for mero-
penem, imipenem and piperacillin/tazobactam (8/1).
Oxacillin susceptibility of Staphylococci was determined
by each individual centre using routine methodology. The
detail of each method was provided by each participant.
Etest method was used by each participant in order to
determine MICs for the following agents: meropenem,
imipenem and piperacillin/tazobactam (tazobatam at one
concentration of 4 mg/L) according to the manufacturer's
recommendations. All aerobic bacteria were tested onto
Mueller Hinton agar. The medium was supplemented
with 5% sheep blood for S. pneumoniae susceptibility
testing. Susceptibilities of anaerobes were tested in a cen-
tralized laboratory. Meropenem, imipenem and pipera-
cillin/tazobactam were tested by agar dilution method
onto Brucella medium (DIFCO) according CLSI M11 A2
reference method and Etest method was realized on the
carbapenems (meropenem, imipenem) only.
All bacteria were centralized and sent to a specific labo-
ratory. Antimicrobial susceptibility testing was deter-
mined by Agar dilution reference method and disk
diffusion tests using 30 μg disks (Biorad Laboratories,
France) were performed for meropenem according to the
CA-SFM recommendations [11]. The antimicrobials were
obtained from the manufacturers: meropenem (Astra-
Zeneca Pharmaceuticals, France) imipenem (Merck Lab-
oratory, France) piperacillin/tazobactam (Wyeth
Pharmaceuticals, France). The antimicrobials were tested
at the following dilution range: meropenem and imi-
penem: from 0.016 to 256 mg/L; piperacillin/tazobactam:
from 0.016/4 to 1,024/4 mg/L. MICs interpretative crite-
ria followed published guidelines established by the CA-
SFM (2006) or EUCAST (2006) where applicable. Quality
controls including the following ATCC strains or CIP
strains (Pasteur Institute Collection) were tested by each
centre on the day of testing: E. coli ATCC 25922, S. pneu-
moniae CIP 104485, P. aeruginosa ATCC 27853, Staphy-
lococcus aureus ATCC 25923.
Beta lactamase screening
When suspected, Gram negative bacilli were screened for
Expanded-Spectrum-Beta-Lactamase activity (ESBL)
according to the "100 recommendations on nosocomial
infections" from the French Health Ministry [13]; EBSL
activity was confirmed by in vitro synergy between third
generation cephalosporins and clavulanate (2 mg/L).
Hyper or depressed production of AmpC beta-lactamase
was identified by cloxacillin and by high level resistance
to cephalosporins and piperacillin/tazobactam, with no
change in susceptibility in the presence of clavulanate. All
P. aeruginosa and Acinetobacter with an elevated carbap-
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Page 3 of 9enem MIC result (≥ 2 mg/L) were screened for the pres-
ence of a metallo β-lactamase or another serine β-
lactamase, using Etest beta-lactamase strip (AB Biodisk
laboratories: Etest + EDTA and Etest + clavulanate) in
presence or in absence of a concentration of cloxacillin in
order to inhibit the presence of AmpC cephalosporinase.
Ethical conduct of the study
The study has been conducted in accordance with "rec-
ommendations guilding physicians in biomedical
research involving human patients " (declaration of Hel-
sinki 1964). The study did not involved biological mate-
rial or gentically modified organisms. All the strains
involved in the study came from routine samples without
any additionnal material.
Statistical analysis
The statistical significance tests of differences between
centres and between the two methods were carried out
using analysis of variance and Student's t test. MICs ver-
sus zone diameter scattergram was prepared for mero-
penem. Very major error (VME) was defined as a
difference superior of 2 log2 between the MICs carried
out by the two methods, major error (ME) as a difference
of 2 log2 and minor error (mE) as a difference of 1 log2.
Results
A total of 1071 isolates were included in this study. They
were isolated from bacteremia, (57%) peritonitis (11%),
pneumonia (13%) or bronchitis (17%) and wound infec-
tions (2%).
In vitro susceptibility results
Table 1 shows the ratio of susceptible strains to antibiot-
ics, determined by the local study participants by routine
methods: agar diffusion (56%), broth dilution (VITEK
[36%] or ATB API [8%]). Table 1 also compares the rates
of susceptible strains, according to the CA-SFM criteria,
obtained for meropenem, imipenem and piperacillin/
tazobactam, by the centralized agar dilution method and
locally determined by Etest method.
Table 2 summarizes the MIC values inhibiting 50%
(MIC50), 90% (MIC90) as well as the MIC range and the
percentage of susceptible strains obtained by centralized
agar dilution method according to EUCAST criteria. Fig-
ure 1 shows the concordance between disk zone diameter
(mm) and MICs values for meropenem.
Gram-negative pathogens
Susceptibility testing, determined by local participants,
showed that carbapenems were the most effective drugs
against Enterobacteriaceae and Acinetobacter, whereas
piperacillin/tazobactam was the most effective drug
against other non fermenter bacilli. The incidence of
ESBL producers was 2% among E coli, 5% among other
Enterobacteriaceae (2.5% among Klebsiella pneumoniae)
and 0% among all non fermenter bacilli. No metallo beta-
lactamase has been identified in P. aeruginosa.
Results obtained by agar dilution method demonstrated
the lowest MICs values with meropenem for Enterobacte-
riaceae. MICs of meropenem were frequently 2-fold
lower than MICs of imipenem for Enterobacteriaceae and
P. aeruginosa. MICs observed for carbapenems in non-
fermenter Gram-negative bacilli were higher. Following
EUCAST breakpoints, no E. coli resistant to carbapen-
ems were identified. One Enterobacter cloacae isolate was
resistant both to imipenem and meropenem (MIC = 16
mg/L) and two Proteus mirabilis showed an intermediate
susceptibility to imipenem (MICs = 4 mg/L); all other
Enterobacteriaceae were fully susceptible to carbapen-
ems. Following EUCAST criteria, the same proportion of
susceptible strains was observed for meropenem and imi-
penem. Among non fermenter bacilli other than P. aerug-
inosa, one Acinetobacter and one Alcaligenes were
resistant to meropenem (MICs: 16 mg/l) but respectively
intermediate or susceptible (MIC respectively 8 mg/l and
2 mg/l) to imipenem. Figure 1 displays the scattergram of
meropenem MICs values versus disc diffusion zone
diameters. Error rate (1.6% of minor errors observed with
Gram-negative bacilli) was within an acceptable range.
Piperacillin/tazobactam demonstrated very good activity
against Gram negative bacilli, particularly against non P.
aeruginosa, aerobes, and bacilli. Discrepancies, which are
the most important with that antibiotic, are related to the
combination of piperacillin and tazobactam at various
concentrations depending the method used.
Gram-positive pathogens
The in vitro activity of antimicrobials against Gram posi-
tive pathogens is displayed on Table 1. A total of 410
pathogens were tested. Table 2 gives the MIC50, the
MIC90, the range and the percentage of susceptible
strains. Against Gram-positive pathogens, imipenem fre-
quently showed MICs one or two-fold lower than mero-
penem without any significant difference between the
two compounds (p > 0.05). All strains were susceptible to
imipenem, meropenem and piperacillin/tazobactam.
Anaerobes
Figure 2 shows the MIC cumulative curves determined by
agar dilution method. The best activity was observed
with meropenem and imipenem (MIC90 = 0.5 mg/L), fol-
lowed by imipenem (MIC90 = 8 mg/L).
Method comparison for Carbapenem MICs results
Comparison between agar dilution method and Etest
method shows correlations of 0.72 for meropenem and
0.74 for imipenem. Table 3 illustrates that 40% (n = 367)
of the results were identical for meropenem and 23%
(210) for imipenem. Respectively, for meropenem and
imipenem, 81.4% and 61% of the strains tested were
within +/- 1 log2 (mE) dilution and 96.6% and 91.5%
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le 1: Susceptibility pattern of nosocomial infection agents obtained at local and central laboratories.wTab
Drugs % Susceptibility (Number tested)
Locally determined Centralized
Routine Etest Agar DM
Escherichia coli
Meropenem 100 (92) 100 (139) 100 (139)
Imipenem 100 (139) 100 (139) 100 (139)
Piperacillin/tazobactam* 82 (139) 89 (139) 90 (139)
Enterobacteriaceae (other than E coli)
Meropenem 100 (86) 99 (139) 99 (139)
Imipenem 99 (139) 97 (139) 97 (139)
Piperacillin/tazobactam* 78 (139) 86 (139) 99 (139)
Pseudomonas aeruginosa
Meropenem 87 (87) 91 (129) 95 (129)
Imipenem 78 (137) 70 (129) 84 (129)
Piperacillin/tazobactam* 88 (136) 89 (129) 90 (129)
Acinetobacter
Meropenem 88 (50) 87 (86) 95 (79)
Imipenem 94 (84) 94 (86) 97 (79)
Piperacillin/tazobactam* 79 (82) 80 (86) 100* (79)
Other non fermentative bacteria
Meropenem 73 (33) 89 (33) 88 (33)
Imipenem 85 (41) 87 (33) 88 (33)
Piperacillin/tazobactam* 90 (41) 97 (33) 90 (33)
Staphylococcus aureus (susceptible to methicillin)
Meropenem - 100 (145) 100 (145)
Imipenem - 100 (145) 100 (145)
Piperacillin/tazobactam* - 100 (145) 100 (145)
Coagulase negative staphylococci (susceptible to methicillin)
Meropenem - 100 (129) 100 (129)
Imipenem - 100 (129) 100 (129)
Piperacillin/tazobactam* - 100 (129) 100 (129)
Streptococcus pneumoniae
Meropenem - 100 (136) 100 (136)
Imipenem - 100 (136) 100 (136)
Piperacillin/tazobactam* - 100 (136) 100 (136)
*Tazobactam: 4 mg/L
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higher Etest MIC result was observed among these
results for the two compounds (p < 0.01). The trend
toward a higher Etest MIC was higher for imipenem (1.1
log2 dilution) than for meropenem (0.5 log2 dilution).
Factors influencing inter method categorical MIC errors
Three percent of VME (31 strains) were observed for
meropenem. Gram-negative bacilli were over represented
with 27/31 strains causing VME. All bacterial groups
were represented. We did not identify any influence of a
centre effect. Among the 15 centres, 0 to 6 VME per cen-
tre were observed. The range of agreement among the 15
centres was 68% to 98% (within +/- 1log).
Seventy nine ME (8.5%) were observed with imipenem.
Gram-negative bacilli (GNB) or Gram-positive cocci
(GPC) were involved (8% of the GNB and 7% of the GPC).
A significant centre effect was observed (p < 0.01): 57% of
ME observed with GPC were due to 2 centres. Quality
controls realized by each participant during the study
allowed the identification of errors by the two local par-
ticipants. Among the 15 centres, 10 had 0% to 5% of ME,
3 had 7 to 16% of ME and had not been identified by the
quality control. Two had more than 30% of ME.
Discusion and Conclusions
This study was the first national prospective surveillance
study assessing antimicrobial activity of meropenem
against recent clinical isolates from French hospitals.
Antimicrobial susceptibility surveillance studies play a
fundamental role in the fight to control resistant organ-
isms. Harmonization between methods and interpreta-
tions are important to compare the results of various
surveys located in different geographic areas [14,15]. The
EUCAST group has provided progress toward harmoni-
zation of susceptibility testing methods used in European
Nations and an international consensus on breakpoint
definitions. Since 2008, the CA-SFM recommends the
EUCAST methods and breakpoints. In this study, we
report that meropenem, imipenem and piperacillin/
tazobactam are very active against Gram-negative bacilli,
including Enterobacteriaceae, P. aeruginosa, Acineto-
bacter and other non fermenter-bacilli. The susceptibility
data obtained from this multicentre study were similar to
data previously published for studies conducted in Can-
ada and other European countries [9,16]. Over the last 5
years, E coli susceptibility worldwide has shown a trend
to decrease, in particular to fluoroquinolones and beta-
Figure 1 Scattergram comparing meropenem disk zone diameters and log MICs by using agar dilution method for 725 strains (EUCAST val-
ues). Minor errors figure in full circles.
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le 2: Antimicrobial activity of meropenem, imipenem and piperacillin/tazobactam against 1071 pathogens lTab
determined by agar dilution reference method.
Species (number tested) MICs (mg/L) % Susceptiblity
Drugs
MIC50 MIC90 Range EUCAST
Escherichia coli (139)
Meropenem 0.016 0.016 0.016-0.032 100
Imipenem 0.064 0.125 0.032-0.5 100
Piperacillin/tazobactam* 2 8 0.25-128 90
Enterobactericeae (other than E coli) (139)
Meropenem 0.032 0.064 0.016-16 99
Imipenem 0.125 1 0.032-16 98
Piperacillin/tazobactam* 2 16 0.125-128 90
Pseudomonas aeruginosa (129)
Meropenem 0.5 4 0.064-16 84
Imipenem 2 16 0.5-32 84
Piperacillin/tazobactam* 8 32 0.25-256 90
Acinetobacter (86)
Meropenem 0.5 2 0.125-16 94
Imipenem 0.5 1 0.125-8 98
Piperacillin/tazobactam* 0.032 2 0.032-16 100*
Other non fermentative bacteria (30)
Meropenem 0.5 2 0.03-16 93
Imipenem 1 2 0.125-8 97
Piperacillin/tazobactam* 2 8 0.032-64 96
Staphylococcus aureus (susceptible to methicillin) (145)
Meropenem 0.125 0.125 0.032-1 100
Imipenem 0.032 0.064 0.016-0.25 100
Piperacillin/tazobactam* 1 2 0.064-8 100
Coagulase negative staphylococci (susceptible to methicillin) (129)
Meropenem 0.064 0.125 0.032-0.5 100
Imipenem 0.016 0.032 0.008-0.125 100
Piperacillin/tazobactam* 0.5 1 0.016-2 100
Streptococcus pneumoniae (136)
Meropenem 0.016 0.25 0.016-0.25 100
Imipenem 0.016 0.125 0.016-0.25 100
Piperacillin/tazobactam* 0.25 4 0.016-8 100
Anaerobes (138)
Meropenem 0.032 0.5 <0.016-4 100
Imipenem 0.064 0.5 <0.016-8 100
Piperacillin/tazobactam* 0.5 8 <0.016-32 100
*Tazobactam: 4 mg/L
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producers and/or of an increase of AmpC [16-20]. Mero-
penem and imipenem demonstrate good activity against
Enterobacteriaceae, including strains producing ESBLs or
AmpC (100% for E coli, 99% for other Enterobacteri-
aceae), meropenem usually being 2 to 4 fold more potent
than imipenem [21-23]. Susceptibility of Acinetobacter
was close to 94 to 98% which is similar to other studies
reporting susceptibility in Europe and the USA [8,16]. In
this report, piperacillin/tazobactam was the most potent
antibiotic against P.aeruginosa (90% of susceptible strains
versus 84% for carbapenems) as reported in other studies
Figure 2 Comparative activity of antibiotics against anaerobes. Cumulative curves of MICs realized by agar dilution reference method.
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Table 3: Variation of meropenem MIC and imipenem MIC results obtained by Etest method realized by local participants, 
and by agar dilution reference method realized by a centralized centre (anaerobes excluded).














Meropenem n = 923 7 9 78 367 306 132 24 +0.5
(%) (0.8) (2.2) (8.5) (40) (33) (14) (2.5)
Imipenem n = 923 5 12 37 210 312 273 74 +1.1
(%) (0.5) (1.3) (4) (22.7) (33.5) (29.7) (8)
* Trend in MIC when compared Etest/Agar dilution method
VME: very major error - ME: major error - mE: minor error
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very good activity with low MICs against Gram-positive
pathogens (MSSCN, MSSA and S. pneumoniae).
Communication of national and regional surveillance
data are important to enable local prescribing practices,
but in reality, every day antibiotic therapy is based on the
sensitivity of antibiotic produced locally. Numerous stud-
ies have demonstrated the validity of the Etest method
compared to the agar dilution method. The variability of
inter-laboratory results is always tested by using refer-
ence strains but the statistical analysis of the centre
results compared the global data is able to give rise to
important informations, it reflects the reality of the daily
work. The rate of agreement varies relatively to the anti-
biotic tested or the bacterial species [24-26]. The agree-
ment (including minor errors) observed between the 2
testing methods was >80% for meropenem, but was low
for imipenem (61%). The VME for meropenem were
observed in Gram-negative bacilli, whereas there was no
difference between Gram-negative bacilli and Gram-pos-
itive cocci for imipenem. In general, MIC values obtained
using the Etest method were commonly higher than val-
ues obtained using agar dilution method. On occasion,
interpretation of the MIC could have significant conse-
quences on result reporting (S, I, R) to the physician and
subsequent prescribing. Analysis of the VME showed that
no particular species was concerned but 2 centres pre-
sented VME (p < 0.05). This observation suggested us
that it could be due to a local technical problem such as
inapropriate storage. Carbapenems and particularly imi-
penem are unstable antibiotics. The humidity could alter
the quality of the strips and could modify the results.
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